Johnson & Johnson

Following completion of the exchange offer, Johnson & Johnson retains approximately 9.5% of the outstanding shares of Kenvue common stock.

The weight of the science does not support any claim that our talc products cause cancer.

Consumer brands including Tylenol, Band-Aid Brand Adhesive Bandages and Johnson’s Baby are owned by Kenvue Inc., which has been an independent publicly traded company since August 2023.

The judgment against J&J is reversed in part as to all seventeen Non-Resident Plaintiffs for lack of personal jurisdiction.

We further enter judgment for $900 million in punitive damages against JJCI and $715,909,091 in punitive damages against J&J.

The jury awarded each individual Plaintiff $25 million in compensatory damages, totaling $550 million, with judgment entered jointly and severally against Defendants. The jury awarded $4.14 billion in punitive damages, with J&J responsible for $3.15 billion and JJCI responsible for $990 million.

J&J is JJCI’s parent company.

Defendants are both incorporated and headquartered in New Jersey.

Johnson & Johnson Consumer Inc. (JJCI) is voluntarily recalling all lots of five NEUTROGENA® and AVEENO® aerosol sunscreen product lines to the consumer level.

J&J’s baby powder is safe and does not cause cancer.

in response to a U.S. Food and Drug Administration (FDA) test indicating the presence of sub-trace levels of chrysotile asbestos contamination (no greater than 0.00002%) in samples from a single bottle purchased from an online retailer.

The pharma will not appeal the decision and will instead “return to the tort system to litigate and defeat these meritless talc claims.”

In a statement following the dismissal, J&J insisted that its settlement plan was “supported by the overwhelming majority of the claimants.”

According to its press statement on Tuesday, J&J has already settled 95% of the suits related to mesothelioma linked to talc and closed all State consumer protection claims.

J&J and its subsidiary, Red River Talc, had proposed a $9 billion bankruptcy package to settle cancer claims linked to its talc product.

The deal must be accepted by 95% of the ovarian cancer claimants in state or federal court before it becomes final.

J&J’s vice president of litigation, Erik Haas, said the claims were “meritless” and that the company was willing to settle in order to get closure.

it has reached a historic uncapped global settlement with J&J, Company to pay a minimum $5.8 billion settlement to resolve all current and pending talcum powder claims in MDL No. 2738 and related state court proceedings.

alleging Johnson’s Baby Powder has caused ovarian cancer and mesothelioma.

But more followed into the tens of thousands.

J&J’s stated goal was to isolate the talc liabilities in a new subsidiary

LTL Management LLC (“LTL”), holding principally Old Consumer’s liabilities relating to talc litigation and a funding support agreement from LTL’s corporate parents

has reached an agreement for a comprehensive resolution of the remaining talc litigation with the plaintiff firms leading the federal Multi-District Litigation (MDL) and related state court proceedings

Calls for per claim payments, with a $5.5 billion commitment by the Company and the first payment of no more than $3 billion to be made in 2027 and no additional payments due before 2028.

Company has prevailed in 16 of 17 ovarian cases tried in the last 11 years

Today, the U.S. Bankruptcy Court for the Southern District of Texas denied the request by Johnson & Johnson (NYSE: JNJ) (the “Company”) subsidiary Red River Talc LLC (“Red River”) to confirm its proposed prepackaged bankruptcy plan

J&J’s stated goal was to isolate the talc liabilities in a new subsidiary so that entity could file for Chapter 11 without subjecting Old Consumer’s entire operating enterprise to bankruptcy proceedings.